What is PT-141? What it does, benefits and what the evidence shows

PT-141 is the research name for bremelanotide, a melanocortin-receptor agonist peptide. Unlike most compounds in this series, it's not purely a grey-market research chemical: FDA approved it in June 2019 under the brand name Vyleesi, for one specific, narrow use — an as-needed injectable treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. Most of what circulates about PT-141 online, though, is about a different use the approval doesn't cover: off-label use, overwhelmingly by men, for erectile dysfunction or general sexual response, which is a separate and much less settled body of evidence.

What PT-141 is and how it works

Bremelanotide is a melanocortin receptor (MCR) agonist that activates several melanocortin receptor subtypes without much selectivity between them. According to the FDA-approved label, MC1R and MC4R are thought to be the most relevant subtypes at the approved dose, and neurons carrying MC4R are found across the central nervous system, and the drug is generally described as acting through the brain rather than directly on genital blood vessels the way PDE5 inhibitors like sildenafil do (VYLEESI prescribing information, DailyMed). The label is candid that the mechanism by which Vyleesi improves HSDD in women "is unknown."

Bremelanotide was developed by Palatin Technologies. It's administered as a subcutaneous injection via an autoinjector under the approved product, and the label is explicit about the boundaries of that approval: Vyleesi "is not indicated for treatment of HSDD in postmenopausal women or in men" and is "not indicated to enhance sexual performance." Everything past that sentence — men using it, women using it outside the specific HSDD diagnosis, anyone using it for performance rather than desire — is off-label use of a drug approved for something else.

What people use it for

What the research actually shows

The approved use: two Phase 3 trials in premenopausal women with HSDD

The approval rests on two identically designed, 24-week, randomized, double-blind, placebo-controlled trials (Study 1, NCT02333071, and Study 2, NCT02338960) that together randomized 1,267 premenopausal women with acquired, generalized HSDD. The co-primary endpoints were change in the Female Sexual Function Index desire domain (FSFI-D) score and change in item 13 of the Female Sexual Distress Scale (FSDS-DAO), a measure of desire-related distress. In Study 1, FSFI-D improved by a mean of 0.5 points versus 0.2 for placebo (p=0.0002); in Study 2, by 0.6 versus 0.2 (p<0.0001). FSDS-DAO item 13 improved by -0.7 versus -0.4 in both studies (p<0.0001 in Study 1, p=0.0053 in Study 2) (VYLEESI prescribing information, DailyMed). Those are modest effect sizes on a subjective scale, which is typical for this category of drug, but they're the result of the randomized, controlled, adequately powered trial design that most peptides in this series simply don't have behind them — which is exactly why this is the one compound here with an "Approved use" row at all. The two studies were followed by a 52-week open-label extension in which 684 of the original patients continued on bremelanotide, giving FDA a longer look at tolerability beyond the initial 24 weeks before approval (VYLEESI prescribing information, DailyMed).

The separate, older history: bremelanotide in men

Before it was a women's-health drug, bremelanotide was studied primarily as a potential erectile dysfunction treatment for men, and under a different administration route. In the early-to-mid 2000s, Palatin ran clinical studies of intranasal and subcutaneous bremelanotide in men, work that was published in peer-reviewed journals including the International Journal of Impotence Research. Palatin's own later public disclosures describe that program as having "conducted multiple clinical studies of monotherapy [bremelanotide] and combination therapy [bremelanotide] plus a PDE5i" showing statistically significant improvements in men (Palatin Technologies press release, June 20, 2024).

That program did not lead to an approval for men. In September 2007, Palatin disclosed that FDA had "raised serious concerns about the acceptable benefit/risk ratio to support the progression of bremelanotide into Phase 3 studies" for erectile dysfunction, and Palatin ended its collaboration with King Pharmaceuticals and reacquired full rights to the drug rather than proceeding to Phase 3 in the general ED population under the intranasal formulation (Palatin Technologies press release, September 10, 2007, via SEC filing). The company's later, subcutaneous reformulation is what eventually went through Phase 3 testing in women and became Vyleesi in 2019. The male-ED program, in a different formulation, simply didn't clear the bar FDA set at the time — which is a materially different regulatory history than "it works but nobody's approved it yet."

A current, unresolved attempt: bremelanotide plus a PDE5 inhibitor for men

Palatin has since returned to male ED as a target, this time in combination with an existing PDE5 inhibitor for men whose ED doesn't respond to a PDE5i alone — roughly 30-40% of ED patients, by the company's estimate. In June 2024, Palatin announced an open-label, dose-escalation Phase 2 study enrolling around 50 such men to assess safety and efficacy of the combination (Palatin Technologies press release, June 20, 2024). The announcement said topline data were expected by the end of calendar year 2024 and that a Phase 3 study was expected to start in the first half of 2025. We could not find published results, or a registered ED study of bremelanotide on ClinicalTrials.gov, from any source we could open as of this writing. If you see this combination discussed as an established treatment, know that on the sources we could verify, it's an unapproved research program without a published readout.

Why the same molecule ended up approved for one group and not the other

It's worth being clear about what actually separates PT-141's two regulatory outcomes, because it's not that the female data is strong and the male data is weak. Both populations showed a measurable drug effect in controlled or company-reported studies. What differs is the formulation, the route, the dose-finding path, and which regulatory concern got resolved first: the intranasal route tested in men was tied to blood-pressure concerns in earlier studies, and FDA raised serious concerns about benefit and risk before a general first-line Phase 3 ED program, while the later subcutaneous, self-administered dose tested in women for a distress-based diagnosis cleared the bar for approval. That's a story about development choices and route of administration as much as it is a story about the underlying biology, and it's a big part of why "it's basically Viagra for men" is a misleading way to describe an approval that has nothing to do with men.

Side effects and risks

The approved product's label lists nausea (40% of Vyleesi-treated patients versus 1.3% on placebo in the pivotal trials), flushing (20.3% versus 0.3%), injection site reactions (13.2% versus 8.4%), headache (11.3% versus 1.9%) and vomiting (4.8% versus 0.2%) as the most common adverse reactions. The label also notes transient increases in blood pressure and focal skin hyperpigmentation, which is more likely to be noticeable with repeated use and in patients with darker skin. Vyleesi carries no boxed warning, but it's contraindicated in people with uncontrolled hypertension or known cardiovascular disease (VYLEESI prescribing information, DailyMed).

That safety profile was established for the approved subcutaneous formulation, at the approved use, in premenopausal women. It's worth being direct about why that matters for off-label use: the earlier intranasal formulation tested in men was tied to blood-pressure concerns, and FDA raised benefit/risk concerns about taking it into Phase 3, which is part of why the drug reached the market through a different route, dose, and population than the one most PT-141 grey-market buyers are actually using it for. A safety profile established in one population and formulation doesn't automatically transfer to a different one.

On the grey-market side specifically, our data as of September 29, 2026 showed a clean but small sample: all 10 PT-141 vials in our database returned a purity result of 99% or higher, with a median of 99.78%. Dose ran meaningfully over label — a median of 14.4% over — with 1 of the 10 vials measuring more than 20% over. None of the 10 vials failed our definition (empty, under 95% pure, more than 20% under label, or more than 50% over).

That's a better purity record than most grey-market compounds, but it doesn't tell you anything about whether a given vial is actually bremelanotide at all versus a similarly named melanocortin peptide, and it says nothing about sterility or endotoxin, which independent testers order far less often for this compound than for the higher-volume GLP-1 peptides. A clean purity and dose record answers "is the labeled peptide present at close to the stated amount," not "is this safe to use the way people are actually using it off label."

What the lab tests show

As of September 30, 2026, our database includes 10 PT-141 vials from 7 vendors, drawn from 8 lab reports dated January 2025 through June 2026. Purity looks strong across the board; the figure to watch is the overfill pattern, which is heavier than in many other compounds we track, though the sample is still small enough that a single vendor can move the numbers. Here's how the ranked vendors for PT-141 look right now; the table shows current verdicts and flags any vendor whose failed-vial rate is above 5%. With 10 total vials tested, this table may be short:

Buying smarter

If you're evaluating a specific vendor's PT-141, check their full record on our PT-141 results page — a vendor needs five or more lab reports before we rank them. Treat a vendor-posted COA as a starting point, not proof: how to read a peptide COA and fake peptide COAs cover what to check before trusting a number you didn't see tested yourself.

Because PT-141 also exists as an FDA-approved prescription product for one specific population, the legal and quality picture here is genuinely different from most compounds in this series; is it legal to buy peptides covers the practical risk picture for buying research-labeled versions instead of going through a prescriber. If you do test a grey-market vial, how to get a peptide tested walks through ordering independent identity, purity and quantity results. If your report comes back with a fail, stop using that batch, tell anyone who bought from the same run, bring the report to the vendor, and submit it to VendorVerify.

Database figures without a date update automatically from VendorVerify's lab results; dated figures are snapshots. This isn't medical advice; the grey-market version of PT-141 is sold for research use only and has not been evaluated by FDA for safety or effectiveness outside the approved Vyleesi product and indication.